Except for CBR, which showed a marginally significant difference, no significant differences were observed among the other efficacy endpoints in the subgroups ( Table 3 and Figure 2 ).
← all excerpts
Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma.
1
—
—